Director, Target Biology

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Targets and Mechanisms group within Discovery Biology leverages expertise in cancer biology and deep mechanistic understanding of cancer-relevant pathways to identify and characterize high-priority oncology targets for our tri-complex inhibitor (TCI) platform. We are looking for an experienced drug hunter to lead the Target Biology team, provide hands-on scientific and people leadership, and work cross-functionally to identify and rapidly assess promising new targets, determine hit identification strategy, and advance screening hits through the early stages of hit-to-lead discovery. The ideal candidate will be a strategic thinker and an accomplished scientist with experience identifying and vetting targets for oncology programs, familiarity with different targeting modalities, including molecular glues, and hands-on hit to lead experience. In this role you will: Lead a team of scientists focused on target identification, prioritization, and biological validation. Work cross-functionally with partners in Medicinal Chemistry, Structural Biology, Discovery Biology, Translational Research, and Cancer Immunology to prioritize oncology targets, implement hit discovery plans, and drive progression from hit identification through lead generation. Collaborate with the Translational Research function to apply learnings from clinical and preclinical studies to inform new target identification and prioritization. Spearhead innovative approaches and technologies for target discovery and hit identification, specifically in the context of hard-to-drug oncology targets. Provide scientific leadership to the team, including technical guidance, coaching, and mentoring. Foster a culture of curiosity, scientific rigor, and excellence, driven by RevMed’s core values and commitment to improving patients’ lives. Implement data-driven decision-making processes to prioritize targets and allocate resources effectively. Required Skills, Experience and Education: We are looking for a driven team leader and an excellent team player to guide the Target Biology team and support overall Discovery Biology efforts. PhD in chemical biology, cell-biology, biochemistry, or a related scientific discipline. Minimum of 10 years of industry experience, ideally in early-stage drug discovery. Experience as a team leader in an industry setting with demonstrated ability to build strong cross-functional relationships and effectively drive early discovery programs. Proven problem solver with strong scientific background and expertise in experimental design and data interpretation. Excellent communication and decision-making skills. Preferred Skills: Knowledge of molecular glue discovery, cellular models, phenotypic screening, and target identification by chemical labeling. Familiarity with multi-omics data, genetic screens (e.g., synthetic lethality) and their application in early discovery. Experience applying advanced analytical techniques (e.g. AI and ML) to generate hypotheses from large, multidimensional data sets. Project team leadership experience in early-stage discovery programs. Experience working with different modalities, such as small molecules, biologics, and molecular glues. #LI-Hybrid #LI-LN1